Are Clinical Trial Participants Monitored More Closely?
Dr. Sangmin Lee discusses the monitoring of clinical trial participants and the measures taken for patient safety.
Dr. Sangmin Lee is a hematologist-oncologist specializing in blood disorders and blood cancers at Weill Cornell Medicine and New York Presbyterian Hospital.
See More From The Fact or Fiction? AML Series
Related Resources
|
|
|
Transcript:
Patricia:
How about this next one? I am monitored more closely in a clinical trial.
Dr. Lee:
In some cases, it’s true. Clinical trials do have certain monitoring visits, in terms of doctor’s visits, laboratory tests, and physical exams.
The purpose of that is to make sure that it is safe. So, the purpose of monitoring closely, in a lot of cases, is for the patient’s safety. We are testing drugs in a lot of clinical trials, for which the complete safety profile, as well as efficacy profile, is not known. So, the purpose of closer monitoring is to make sure whatever we’re doing is safe, and if there are any unexpected side effects, then it allows us to address the side effects, as well. So, it’s mainly for patients’ safety.
